Last reviewed · How we verify
Dianeal
At a glance
| Generic name | Dianeal |
|---|---|
| Sponsor | Vantive Health LLC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. (PHASE3)
- Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients (PHASE3)
- IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients (PHASE4)
- IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients (PHASE3)
- Open-label, Randomized Trial to Determine the Effect of Icodextrin Versus Dextrose (Dianeal 2.5%) in HOMA IR (PHASE4)
- Direct Resuscitation of the Open Peritoneum (NA)
- Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis (PHASE4)
- Zero Sodium Peritoneal Dialysate Protocol Pilot Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dianeal CI brief — competitive landscape report
- Dianeal updates RSS · CI watch RSS
- Vantive Health LLC portfolio CI